Typhim Vi Vaccine Against Typhoid Fever: A Clinical Trial In Kenya.
![Thumbnail](/bitstream/handle/11295/47271/ABSTRACT.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
1995Author
Mirza, N.B.
Wamola, I.A.
Estambale, B.A.
Mbithi, E.
Poillet, M.
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Safety, tolerance and immunogenicity of the purified Vi polysaccharide vaccine (Typhim Vi) against typhoid fever was evaluated in primary school children aged 5-15 years. A total of 435 children were vaccinated, each with a single intramuscular injection in the left deltoid muscle. One hundred and ten children were randomly selected for blood samples on day 0 (pre vaccination) and day 30 (post vaccination). Vi antibodies studied by Radio immuno assay (RIA) on 97(88%) paired sera showed a seroconversion rate of 76.2% and seroprotection rate after vaccination was 74.2%, while 6.2% of children already had protective immunity before vaccination. The vaccine was well tolerated. Most commonly reported reactions were mild pain at site of injection (83%), and a few complained of mild swelling (4.6%), induration (1.1%), itching (1.1%) and headaches (1.4%). All reactions were of mild severity and disappeared within 24 to 48 hours.
URI
http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/47271http://www.ncbi.nlm.nih.gov/pubmed/7796767
Citation
East Afr Med J. 1995 Mar;72(3):162-4.Collections
- Faculty of Health Sciences (FHS) [10378]